The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model

John B Christoforidis, Robert Ricketts, Cedric Pratt, Jordan Pierce, Scott Bean, Michael Wells, Xiaoli Zhang, Krista la Perle

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To investigate the effect of intravitreal pegaptanib, bevacizumab, and ranibizumab on blood-vessel formation during cutaneous wound healing in a rabbit model and to compare this effect to placebo controls. Methods: Forty New Zealand albino rabbits underwent full thickness cutaneous wounds using 6-mm dermatologic punch biopsies. The rabbits were assigned to four groups of ten, each receiving intravitreal injections of pegaptanib, bevacizumab, ranibizumab, or no injection (untreated controls). Five rabbits from each group underwent wound harvesting on day 7 and five from each group on day 14. The skin samples were stained with hematoxylin and eosin (HE), Masson's trichrome (MT), and CD34 for vascular endothelial cells. Semiquantitative evaluation of HE- and MT-stained slides was performed by one pathologist. Quantitative assessment of mean neovascularization (MNV) scores was obtained from five contiguous biopsy margin 400× fields of CD34-stained sections by four independent observers. Results: Week 1 MNV scores in CD-34 stained sections were: untreated controls: 11.51 ± 4.36; bevacizumab: 7.41 ± 2.82 (P = 0.013); ranibizumab: 8.71 ± 4.08 (P = 0.071); and pegaptanib: 10.15 ± 5.59 (P = 0.378). Week 2 MNV data were: untreated controls: 6.14 ± 2.25; bevacizumab: 7.25 ± 2.75 (P = 0.471); ranibizumab: 4.53 ± 3.12 (P = 0.297); and, pegaptanib: 6.35 ± 3.09 (P = 0.892). Interobserver variability using intraclass correlation coefficient was 0.961. Conclusions: At week 1, all three anti-VEGF agents had suppressed MNV scores compared to controls. Although not statistically significant, there was an inhibitory trend, particularly with bevacizumab and ranibizumab. These effects were diminished at 2 weeks, reflecting a transition between the proliferative and remodeling phases of wound healing.

Original languageEnglish (US)
Pages (from-to)61-69
Number of pages9
JournalClinical Ophthalmology
Volume6
Issue number1
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Wound Healing
Vascular Endothelial Growth Factor A
Rabbits
Hematoxylin
Eosine Yellowish-(YS)
Skin
Biopsy
Placebo Effect
Intravitreal Injections
Observer Variation
Wounds and Injuries
Blood Vessels
Endothelial Cells
Bevacizumab
Ranibizumab
Injections
pegaptanib

Keywords

  • Anti-VEGF
  • Bevacizumab
  • Intraocular
  • Pegaptanib
  • Ranibizumab
  • Wound healing

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model. / Christoforidis, John B; Ricketts, Robert; Pratt, Cedric; Pierce, Jordan; Bean, Scott; Wells, Michael; Zhang, Xiaoli; la Perle, Krista.

In: Clinical Ophthalmology, Vol. 6, No. 1, 2012, p. 61-69.

Research output: Contribution to journalArticle

Christoforidis, JB, Ricketts, R, Pratt, C, Pierce, J, Bean, S, Wells, M, Zhang, X & la Perle, K 2012, 'The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model', Clinical Ophthalmology, vol. 6, no. 1, pp. 61-69. https://doi.org/10.2147/OPTH.S28275
Christoforidis, John B ; Ricketts, Robert ; Pratt, Cedric ; Pierce, Jordan ; Bean, Scott ; Wells, Michael ; Zhang, Xiaoli ; la Perle, Krista. / The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model. In: Clinical Ophthalmology. 2012 ; Vol. 6, No. 1. pp. 61-69.
@article{ef4ddb78756f425a98fb0052b528d52d,
title = "The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model",
abstract = "Purpose: To investigate the effect of intravitreal pegaptanib, bevacizumab, and ranibizumab on blood-vessel formation during cutaneous wound healing in a rabbit model and to compare this effect to placebo controls. Methods: Forty New Zealand albino rabbits underwent full thickness cutaneous wounds using 6-mm dermatologic punch biopsies. The rabbits were assigned to four groups of ten, each receiving intravitreal injections of pegaptanib, bevacizumab, ranibizumab, or no injection (untreated controls). Five rabbits from each group underwent wound harvesting on day 7 and five from each group on day 14. The skin samples were stained with hematoxylin and eosin (HE), Masson's trichrome (MT), and CD34 for vascular endothelial cells. Semiquantitative evaluation of HE- and MT-stained slides was performed by one pathologist. Quantitative assessment of mean neovascularization (MNV) scores was obtained from five contiguous biopsy margin 400× fields of CD34-stained sections by four independent observers. Results: Week 1 MNV scores in CD-34 stained sections were: untreated controls: 11.51 ± 4.36; bevacizumab: 7.41 ± 2.82 (P = 0.013); ranibizumab: 8.71 ± 4.08 (P = 0.071); and pegaptanib: 10.15 ± 5.59 (P = 0.378). Week 2 MNV data were: untreated controls: 6.14 ± 2.25; bevacizumab: 7.25 ± 2.75 (P = 0.471); ranibizumab: 4.53 ± 3.12 (P = 0.297); and, pegaptanib: 6.35 ± 3.09 (P = 0.892). Interobserver variability using intraclass correlation coefficient was 0.961. Conclusions: At week 1, all three anti-VEGF agents had suppressed MNV scores compared to controls. Although not statistically significant, there was an inhibitory trend, particularly with bevacizumab and ranibizumab. These effects were diminished at 2 weeks, reflecting a transition between the proliferative and remodeling phases of wound healing.",
keywords = "Anti-VEGF, Bevacizumab, Intraocular, Pegaptanib, Ranibizumab, Wound healing",
author = "Christoforidis, {John B} and Robert Ricketts and Cedric Pratt and Jordan Pierce and Scott Bean and Michael Wells and Xiaoli Zhang and {la Perle}, Krista",
year = "2012",
doi = "10.2147/OPTH.S28275",
language = "English (US)",
volume = "6",
pages = "61--69",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model

AU - Christoforidis, John B

AU - Ricketts, Robert

AU - Pratt, Cedric

AU - Pierce, Jordan

AU - Bean, Scott

AU - Wells, Michael

AU - Zhang, Xiaoli

AU - la Perle, Krista

PY - 2012

Y1 - 2012

N2 - Purpose: To investigate the effect of intravitreal pegaptanib, bevacizumab, and ranibizumab on blood-vessel formation during cutaneous wound healing in a rabbit model and to compare this effect to placebo controls. Methods: Forty New Zealand albino rabbits underwent full thickness cutaneous wounds using 6-mm dermatologic punch biopsies. The rabbits were assigned to four groups of ten, each receiving intravitreal injections of pegaptanib, bevacizumab, ranibizumab, or no injection (untreated controls). Five rabbits from each group underwent wound harvesting on day 7 and five from each group on day 14. The skin samples were stained with hematoxylin and eosin (HE), Masson's trichrome (MT), and CD34 for vascular endothelial cells. Semiquantitative evaluation of HE- and MT-stained slides was performed by one pathologist. Quantitative assessment of mean neovascularization (MNV) scores was obtained from five contiguous biopsy margin 400× fields of CD34-stained sections by four independent observers. Results: Week 1 MNV scores in CD-34 stained sections were: untreated controls: 11.51 ± 4.36; bevacizumab: 7.41 ± 2.82 (P = 0.013); ranibizumab: 8.71 ± 4.08 (P = 0.071); and pegaptanib: 10.15 ± 5.59 (P = 0.378). Week 2 MNV data were: untreated controls: 6.14 ± 2.25; bevacizumab: 7.25 ± 2.75 (P = 0.471); ranibizumab: 4.53 ± 3.12 (P = 0.297); and, pegaptanib: 6.35 ± 3.09 (P = 0.892). Interobserver variability using intraclass correlation coefficient was 0.961. Conclusions: At week 1, all three anti-VEGF agents had suppressed MNV scores compared to controls. Although not statistically significant, there was an inhibitory trend, particularly with bevacizumab and ranibizumab. These effects were diminished at 2 weeks, reflecting a transition between the proliferative and remodeling phases of wound healing.

AB - Purpose: To investigate the effect of intravitreal pegaptanib, bevacizumab, and ranibizumab on blood-vessel formation during cutaneous wound healing in a rabbit model and to compare this effect to placebo controls. Methods: Forty New Zealand albino rabbits underwent full thickness cutaneous wounds using 6-mm dermatologic punch biopsies. The rabbits were assigned to four groups of ten, each receiving intravitreal injections of pegaptanib, bevacizumab, ranibizumab, or no injection (untreated controls). Five rabbits from each group underwent wound harvesting on day 7 and five from each group on day 14. The skin samples were stained with hematoxylin and eosin (HE), Masson's trichrome (MT), and CD34 for vascular endothelial cells. Semiquantitative evaluation of HE- and MT-stained slides was performed by one pathologist. Quantitative assessment of mean neovascularization (MNV) scores was obtained from five contiguous biopsy margin 400× fields of CD34-stained sections by four independent observers. Results: Week 1 MNV scores in CD-34 stained sections were: untreated controls: 11.51 ± 4.36; bevacizumab: 7.41 ± 2.82 (P = 0.013); ranibizumab: 8.71 ± 4.08 (P = 0.071); and pegaptanib: 10.15 ± 5.59 (P = 0.378). Week 2 MNV data were: untreated controls: 6.14 ± 2.25; bevacizumab: 7.25 ± 2.75 (P = 0.471); ranibizumab: 4.53 ± 3.12 (P = 0.297); and, pegaptanib: 6.35 ± 3.09 (P = 0.892). Interobserver variability using intraclass correlation coefficient was 0.961. Conclusions: At week 1, all three anti-VEGF agents had suppressed MNV scores compared to controls. Although not statistically significant, there was an inhibitory trend, particularly with bevacizumab and ranibizumab. These effects were diminished at 2 weeks, reflecting a transition between the proliferative and remodeling phases of wound healing.

KW - Anti-VEGF

KW - Bevacizumab

KW - Intraocular

KW - Pegaptanib

KW - Ranibizumab

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=84863078521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863078521&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S28275

DO - 10.2147/OPTH.S28275

M3 - Article

C2 - 22275809

AN - SCOPUS:84863078521

VL - 6

SP - 61

EP - 69

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

IS - 1

ER -